Page 88 - 《中国药房》2024年11期

[10] 丁樱，王旋辉，宫春博. 帕博利珠单抗联合化疗方案一线 （5）：408.
治疗晚期或不可切除胆道恶性肿瘤的成本-效用分析 [17] CHEN J A，RIESS J W. Advances in targeting acquired re‐
[J]. 中国药房，2023，34（23）：2891-2895. sistance mechanisms to epidermal growth factor receptor
DING Y，WANG X H，GONG C B. Cost-utility analysis tyrosine kinase inhibitors[J]. J Thorac Dis，2020，12（5）：
of pembrolizumab combined with chemotherapy in the 2859-2876.
first-line treatment of advanced or unresectable biliary [18] LE X N，NILSSON M，GOLDMAN J，et al. Dual EGFR-
tract carcinoma[J]. China Pharm，2023，34（23）：2891- VEGF pathway inhibition：a promising strategy for pa‐
2895. tients with EGFR-mutant NSCLC[J]. J Thorac Oncol，
[11] SHU Y M，ZHANG Q L，HE X C，et al. Cost- 2021，16（2）：205-215.
effectiveness analysis of gefitinib plus chemotherapy ver‐ [19] SAITO H，FUKUHARA T，FURUYA N，et al. Erlotinib
sus gefitinib alone for advanced non-small-cell lung can‐ plus bevacizumab versus erlotinib alone in patients with
cer with EGFR mutations in China[J]. Cancer Manag Res， EGFR-positive advanced non-squamous non-small-cell
2021，13：8297-8306. lung cancer （NEJ026）：interim analysis of an open-label，
[12] LI W Q，LI L Y，CHAI J，et al. Cost-effectiveness analysis randomised，multicentre，phase 3 trial[J]. Lancet Oncol，
of first-line treatments for advanced epidermal growth fac‐ 2019，20（5）：625-635.
tor receptor-mutant non-small cell lung cancer patients[J]. [20] ROSELL R，DAFNI U，FELIP E，et al. Erlotinib and beva‐
Cancer Med，2021，10（6）：1964-1974. cizumab in patients with advanced non-small-cell lung
[13] 陈昭燕，田方圆，徐珽. 贝伐珠单抗联合标准化疗方案治 cancer and activating EGFR mutations （BELIEF）：an in‐
疗复发性宫颈癌患者的成本-效果分析[J]. 中国现代应 ternational，multicentre，single-arm，phase 2 trial[J]. Lan‐
用药学，2020，37（10）：1208-1213. cet Respir Med，2017，5（5）：435-444.
CHEN Z Y，TIAN F Y，XU T. Cost-effectiveness analysis [21] LI X Y，LI W C，HOU L P. A trial-based cost-
of bevacizumab combined with standard chemotherapy in effectiveness analysis of bevacizumab and chemotherapy
patients with recurrent cervical cancer[J]. Chin J Mod versus chemotherapy alone for advanced nonsquamous
Appl Pharm，2020，37（10）：1208-1213. non-small-cell lung cancer in China[J]. Value Health Reg
[14] CAI H F，ZHANG L F，LI N，et al. Lenvatinib versus Issues，2019，18：1-7.
sorafenib for unresectable hepatocellular carcinoma：a [22] RUI M J，LI H C. Cost-effectiveness of osimertinib vs
cost-effectiveness analysis[J]. J Comp Eff Res，2020，9 docetaxel-bevacizumab in third-line treatment in EGFR
（8）：553-562. T790M resistance mutation advanced non-small cell lung
[15] CHEN Y Z，WEN S D，WU Y，et al. Efficacy and safety cancer in China[J]. Clin Ther，2020，42（11）：2159-
of first-generation epidermal growth factor receptor 2170.e6.
（EGFR） tyrosine kinase inhibitors （TKIs） combined with [23] PARODY-RÚA E，GUEVARA-CUELLAR C A. Cost-
chemotherapy or antiangiogenic therapy as first-line treat‐ effectiveness of the addition of bevacizumab to first-line
ment in patients with EGFR-mutant non-small cell lung chemotherapy with carboplatin and paclitaxel in patients
cancer：a systematic review and meta-analysis[J]. Crit Rev with non-small cell lung cancer[J]. Value Health Reg Is‐
Oncol Hematol，2021，163：103393. sues，2020，23：93-98.
[16] SUN R Z，HOU Z S，ZHANG Y K，et al. Drug resistance （收稿日期：2023-10-28 修回日期：2024-04-21）
mechanisms and progress in the treatment of EGFR- （编辑：胡晓霖）
mutated lung adenocarcinoma[J]. Oncol Lett，2022，24

· 1362 · China Pharmacy 2024 Vol. 35 No. 11 中国药房 2024年第35卷第11期